Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The entry "Automated basal and bolus insulin adjustment based on continuous interstitial glucose measurement" does **not** refer to a single molecule, receptor, enzyme, transporter, or other canonical therapeutic target. Instead, it describes an **integrated medical technology**—commonly known as an automated insulin delivery (AID) system or hybrid closed-loop system—that combines three main components: * A **continuous glucose monitor** (CGM), which measures interstitial fluid glucose levels in real time. * An **insulin pump**, which delivers both basal and bolus doses of subcutaneous insulin. * A **control algorithm**, which processes CGM data to automatically adjust the rate of basal and sometimes correctional bolus insulin delivered by the pump[1][2][3][5]. These systems are designed to mimic some functions of the healthy pancreas ("artificial pancreas") by automating much of the day-to-day decision-making required for intensive diabetes management. They are primarily used for people with type 1 diabetes but have also shown benefit in type 2 diabetes requiring intensive therapy[4]. The user typically still needs to manually enter carbohydrate intake before meals; fully automated systems without any manual input are not yet standard. Because this is a description of a *device-based therapeutic approach*, not a molecular entity or biological target amenable to drug binding/modulation, it should be flagged as "not a target" per your conventions. If you need structured information about specific molecules involved—such as the human *insulin receptor*, *GLUT transporters*, etc.—please specify those targets instead.
Algorithm-driven adjustment of basal and bolus insulin delivery based on continuous interstitial glucose measurements from a CGM[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Automated basal and bolus insulin adjustment based on continuous interstitial glucose measurement (AID system).